← Every company
Daiichi Sankyo Co Ltd Patents
What Daiichi Sankyo Co Ltd has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
DSNKY on carbonthat →Filings on file
51
Granted
1
Still pending
50
Filed under
6 names
51 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| IMMUNE INDUCER CONTAINING POLYNUCLEOTIDE-PEPTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION CONTAINING SAMEA61K 47/65, C12N 15/117, A61K 47/64, A61K 47/549, A61K 47/60, A61P 31/00, A61P 37/04, A61P 37/08, A61P 35/00, A61K 39/001156, A61K 39/001192, A61K2039/876, A61K 31/7088, A61K 39/39, A61K2039/55561, A61K2039/572, C07K 7/06, C07K 19/00, C12N2310/17, C12N2310/315, C12N2310/3513, C12N2320/32Filed as Daiichi Sankyo Company, Limited2026-06-05Shinichi Mochizuki | pending |
| COMBINATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND RASG12C INHIBITORA61K 47/68037, A61K 45/06, A61K 47/6889, A61K 47/6851, A61K 47/6857, A61K 47/6849, A61K 47/6855, A61P 43/00, A61P 35/00, A61K 31/519, A61K 39/395, A61K2039/505, A61K2300/00, C07K 16/32, C07K2317/73, C07K2317/77Filed as DAIICHI SANKYO COMPANY, LIMITED2026-03-02Hirokazu SUZUKI | pending |
| METHOD FOR PRODUCING AN ANTIBODY-DRUG CONJUGATE COMPRISING A PURIFICATION STEP USING ACTIVATED CARBON MATERIALFiled as DAIICHI SANKYO COMPANY, LIMITED2025-12-26Atsuki FUKUBA | pending |
| IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATEC07D 491/22, C07K 5/10, Y02P 20/55, A61K 47/65, A61P 35/00, A61K 39/395, C07B2200/13, C07C 237/08, C07D 207/452, C07K 16/18, C07K 16/2827, C07K 16/30, C07K 16/32Filed as DAIICHI SANKYO COMPANY, LIMITED2025-11-11Tatsuya YAMAGUCHI | pending |
| COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITORA61K 47/6801, C07K 16/32, A61K 47/65, A61K 47/6851, A61K 47/6857, A61K 47/6869, A61K 47/545, A61K 47/6849, A61K 47/6855, A61K 47/6835, A61K 47/6859, A61P 43/00, A61P 35/00, A61K 47/68037, A61K 31/337, A61K 31/357, A61K 31/4745, A61K 39/39558, A61K 45/06, A61K2039/505, A61K2300/00, C07K 16/28, C07K 16/2827Filed as DAIICHI SANKYO COMPANY, LIMITED2025-11-11Yusuke OGITANI | pending |
| ANTI-SIRPalpha ANTIBODYA61K 39/395, C07K 16/2803, C07K 16/2896, A61P 43/00, A61P 35/02, A61P 35/00, A61K2039/505, A61K2039/507, C07K 16/28, C07K 16/2863, C07K 16/2887, C07K 16/32, C07K2317/21, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/52, C07K2317/565, C07K2317/71, C07K2317/72, C07K2317/73, C07K2317/732, C07K2317/76, C12N 5/10, C12N 15/63Filed as DAIICHI SANKYO COMPANY, LIMITED2025-10-30Takashi MATOZAKI | pending |
| COMBINATION OF ANTIBODY-DRUG CONJUGATE AND OTHER MEDICINEA61K 47/6849, A61K 47/6889, A61P 35/00, A61K 47/68037, A61K 31/4184, A61K 31/454, A61K 31/4985, A61K 31/519, A61K 31/635, A61K 39/3955, A61K 45/06Filed as DAIICHI SANKYO COMPANY LIMITED2025-10-17Yuji SHINJO | pending |
| COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITORA61K 47/6849, A61K 47/68037, A61K 47/6889, A61K 47/65, A61K 47/6851, A61K 47/545, A61P 13/08, A61P 21/00, A61P 19/00, A61P 43/00, A61P 1/16, A61P 1/18, A61P 17/00, A61P 35/02, A61P 13/10, A61P 13/12, A61P 1/00, A61P 11/00, A61P 15/00, A61P 13/00, A61P 35/00, A61K 31/4745, A61K 31/5355, A61K 31/5377, A61K 39/395, A61K 45/06, A61K2039/505, A61K2039/54, A61K2039/542, C07K 16/2827, C07K2317/24, A61K2300/00Filed as DAIICHI SANKYO COMPANY, LIMITED2025-10-09Len KATSUMATA | pending |
| THERAPEUTIC METHOD FOR LOW-DRUG-SENSITIVITY CANCERS BY ADMINISTRATION OF ANTI-MUC1 ANTIBODY-DRUG CONJUGATEA61K 47/6851, A61K 47/6803, C07K 16/3092, A61K 47/6889, A61K 47/65, A61P 35/02, A61P 13/10, A61P 11/00, A61P 15/00, A61P 35/00, A61K 47/68037, A61K 47/68033, A61K 47/68031, A61K 31/4745, A61K 39/395, C07K 16/18, C07K 16/30, C07K 16/32, C07K2317/77Filed as DAIICHI SANKYO COMPANY, LIMITED2025-10-03Kazuki TAKAHASHI | pending |
| COMBINATION OF ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND HIF-2alpha INHIBITORA61P 1/00, A61K 47/68037, A61K 47/6889, A61K 47/65, A61K 47/6851, A61K 47/6849, A61P 13/08, A61P 1/16, A61P 1/18, A61P 17/00, A61P 13/12, A61P 11/00, A61P 15/00, A61P 19/08, A61P 25/00, A61P 5/14, A61P 35/00, A61K 31/277, A61K 31/4745, A61K 39/395, A61K 45/00, A61K 45/06, A61K2300/00, C07K 1/107, C07K 7/06, C07K 16/00, C07K 16/28, C07K2317/24, C07K2317/77Filed as DAIICHI SANKYO COMPANY, LIMITED2025-09-29Hirokazu SUZUKI | pending |
| COMBINATION OF ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND VEGF INHIBITORA61K 47/6889, A61P 43/00, A61K 47/68037, A61K 47/65, A61K 47/6851, A61K 47/6849, A61P 13/12, A61P 15/00, A61P 35/00, A61K 31/4745, A61K 38/00, A61K 39/395, A61K 39/3955, A61K 45/06, A61K2039/505, A61K2039/545, C07K 7/02, C07K 14/71, C07K 16/00, C07K 16/22, C07K 16/28, C07K 16/2863, C07K 16/2896, C07K 16/30, C07K2317/31, C07K2319/30, A61K2300/00Filed as DAIICHI SANKYO COMPANY, LIMITED2025-09-12Shotaro NAGASE | pending |
| ANTI-LRRC15 ANTIBODYC07K 16/2803, A61P 35/00, A61K2039/505, C07K2317/14, C07K2317/24, C07K2317/565, C07K2317/77, C07K2317/92Filed as DAIICHI SANKYO COMPANY, LIMITED2025-07-25Shunsuke SOMEYA | pending |
| SUBSTITUTED BENZENE COMPOUNDA61P 1/04, C07D 487/04, A61P 25/14, A61P 27/02, A61P 37/00, A61P 17/06, A61P 21/00, A61P 27/06, A61P 37/02, A61P 9/10, A61P 19/06, A61P 25/20, A61P 25/28, A61P 43/00, A61P 1/16, A61P 11/06, A61P 25/02, A61P 25/22, A61P 31/12, A61P 17/00, A61P 19/02, A61P 31/14, A61P 35/02, A61P 3/10, A61P 13/10, A61P 13/12, A61P 25/18, A61P 25/24, A61P 9/04, A61P 11/00, A61P 25/00, A61P 25/08, A61P 25/16, A61P 29/00, A61P 9/14, A61P 35/00, A61K 31/5025, C07D 401/04, C07D 401/06, C07D 471/04, C07D 471/16, C07D 487/16, C07D 491/147, C07D 495/04, C07D 519/00Filed as DAIICHI SANKYO COMPANY, LIMITED2025-07-23Katsushi KATAYAMA | pending |
| EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUGA61P 35/00, A61K 31/443, A61P 35/02, A61K 31/167, A61K 31/282, A61K 31/337, A61K 31/365, A61K 31/4045, A61K 31/44, A61K 31/454, A61K 31/4745, A61K 31/475, A61K 31/502, A61K 31/505, A61K 31/506, A61K 31/513, A61K 31/517, A61K 31/519, A61K 31/555, A61K 31/573, A61K 31/635, A61K 31/675, A61K 31/69, A61K 31/704, A61K 31/7048, A61K 31/706, A61K 31/7068, A61K 39/395, A61K 39/3955, A61K 45/06, A61K2039/505, A61K2300/00, C07K 16/2818, C07K 16/2827, C07K 16/2887Filed as DAIICHI SANKYO COMPANY, LIMITED2025-07-15Daisuke HONMA | pending |
| 2-AZABICYCLO[3.1.1]HEPTANE COMPOUNDC07D 221/22, A61P 25/00, A61K 31/439, A61K 31/444, C07B 59/002, C07D 401/06, C07D 401/10, C07D 405/06, C07D 405/10, C07D 409/10, C07D 413/06Filed as DAIICHI SANKYO COMPANY, LIMITED2025-06-13Akitake YAMAGUCHI | pending |
| ENVIRONMENTALLY-RESPONSIVE MASKED ANTIBODY AND USE THEREOFA61K 47/6801, C07K 14/00, C07K 16/30, A61K 47/6889, A61K 47/62, A61K 47/68, A61K 47/6849, A61P 35/00, A61K 47/68037, A61K 47/68035, C07K 16/28, C07K 16/2863, C07K 16/2896, C07K2317/622, C07K2317/73, C07K2317/92, C07K2319/00, C40B 40/10, G01N 33/531Filed as DAIICHI SANKYO COMPANY, LIMITED2025-05-29Shota KUDO | pending |
| BISPECIFIC ANTIBODYA61P 35/00, A61K 31/7088, C07K 16/2833, C07K 16/30, A61K 35/76, A61K 39/395, A61K 48/00, A61K2039/505, C07K 16/00, C07K 16/2803, C07K 16/2809, C07K 16/3046, C07K 16/3069, C07K 16/32, C07K 16/46, C07K 16/468, C07K2317/21, C07K2317/24, C07K2317/31, C07K2317/32, C07K2317/34, C07K2317/52, C07K2317/522, C07K2317/524, C07K2317/526, C07K2317/528, C07K2317/53, C07K2317/55, C07K2317/56, C07K2317/565, C07K2317/567, C07K2317/622, C07K2317/64, C07K2317/71, C07K2317/73, C07K2317/92, C07K2317/94, C12N 5/0636, C12N 5/10, C12N 15/1037, C12N 15/63, C12N 15/74, C12N 15/80, C12N 15/81, C12N2502/30, C12N2510/00Filed as DAIICHI SANKYO COMPANY, LIMITED2025-05-23Hiroshi SHIKU | pending |
| COMBINATION OF ANTIBODY-DRUG CONJUGATE AND IMMUNE CHECKPOINT INHIBITORA61K 47/6803, C07K 16/2818, A61K 47/65, A61K 47/68, A61K 47/6855, A61K 47/6863, A61P 43/00, A61P 35/02, A61P 35/00, A61K 47/68037, A61K 9/0019, A61K 31/4745, A61K 39/395, A61K 39/39558, A61K 45/00, A61K 47/20, A61K2039/505, A61K2039/507, A61K2039/545, A61K2300/00, C07K 16/32Filed as DAIICHI SANKYO COMPANY, LIMITED2025-04-30Tomomi IWATA | pending |
| 3-PHENYLPROPYLAMINE DERIVATIVEA61K 31/351, C07C 69/78, C07D 309/04, C07C2601/16, C07C2601/14, A61K 47/55, A61P 5/42, A61P 43/00, A61P 5/46, A61P 35/00, A61K 31/216, A61K 31/4025, A61K 31/404, A61K 31/4166, A61K 31/438, A61K 31/4433, A61K 31/445, A61K 31/453, A61K 31/454, A61K 31/4545, A61K 31/4745, A61K 31/496, A61K 31/506, A61K 31/5383, A61K 31/5386, A61K 31/5513, A61K 31/5517, A61K 31/695, C07B2200/13, C07C 69/22, C07C 69/675, C07C 69/738, C07C 69/757, C07D 209/04, C07D 211/14, C07D 211/22, C07D 211/46, C07D 217/04, C07D 235/02, C07D 241/38, C07D 243/14, C07D 307/14, C07D 309/06, C07D 401/04, C07D 401/12, C07D 401/14, C07D 405/10, C07D 405/12, C07D 405/14, C07D 413/12, C07D 471/04, C07D 471/06, C07D 471/10, C07D 487/04, C07D 487/06, C07D 487/10, C07D 491/107, C07D 498/04, C07D 498/06, C07D 498/16, C07D 519/00, C07F 7/0834Filed as DAIICHI SANKYO COMPANY, LIMITED2025-04-11Hideaki KAGEJI | 12606533 |
| METHOD FOR PRODUCING COMPOUND HAVING TWO-BRANCHED N-ACETYL-D-GALACTOSAMINE STRUCTUREC07H 15/04, C07C 271/22, C07D 207/46Filed as Daiichi Sankyo Company, Limited2025-04-03Hiroshi NAGASAWA | pending |
| IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTUREA61P 35/00, A61K 31/395, C07D 471/04, C07D 519/00, A61P 43/00, A61P 35/02, A61K 31/437, A61K 31/4375, A61K 31/44, A61K 31/444, A61K 31/4545, A61K 31/496, A61K 31/506, A61K 31/519, A61K 31/5365, A61K 31/5377, A61K 31/5386, A61K 31/5395, A61K 31/55, A61K 31/551, A61K 39/395, A61K 39/39558, A61K 45/00, A61K 45/06, A61K2039/505, A61K2300/00, C07B 59/002, C07D 471/22, C07D 498/22, C07D 513/22, C07K 16/2818, C07K 16/2827Filed as DAIICHI SANKYO COMPANY, LIMITED2025-04-01Hidenori NAMIKI | pending |
| 3-PHENYLPROPYLAMINE DERIVATIVEC07D 309/06, A61K 31/235, A61K 31/351, A61K 31/4025, A61K 31/4433, A61K 31/453, A61K 31/506, C07C 69/67, C07C 69/73, C07C 69/757, C07D 309/04, C07D 405/10Filed as DAIICHI SANKYO COMPANY, LIMITED2025-03-28Hideaki KAGEJI | pending |
| ANTI-MUC1 ANTIBODY-DRUG CONJUGATEA61K 47/6851, C07K 16/3092, A61K 47/65, A61K 47/545, A61K 47/6803, A61P 35/02, A61P 35/04, A61P 35/00, A61K 47/68037, G01N 33/575, A61K 31/4745, A61K 39/39558, A61K 45/00, A61K 45/06, A61K 47/22, A61K2039/505, B66B 5/22, C07K 16/30, C07K2317/14, C07K2317/24, C07K2317/41, C07K2317/55, C07K2317/565, C07K2317/73, C07K2317/76, C07K2317/92Filed as DAIICHI SANKYO CO., LTD.2025-03-26Johanna GELLERT | pending |
| COMBINATIONS FOR THE TREATMENT OF PROSTATE CANCERFiled as DAIICHI SANKYO COMPANY, LIMITED2025-03-04Kentaro IMAI | pending |
| NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDEC08B 37/00, C08B 37/006, Y02P 20/55, A61K 47/6889, A61K 47/549, C07H 1/00, C07H 3/06, C07H 15/203, C07H 19/04, C07K 16/00, C07K2317/41, C07K2317/52Filed as DAIICHI SANKYO COMPANY, LIMITED2025-02-28Tsuyoshi UEDA | pending |
| ANTIBODY-DRUG CONJUGATE INCLUDING MUTANT Fc REGIONA61K 47/6889, A61K 47/6807, A61P 35/00, A61K 31/7064, A61K 47/68, A61K 47/6849, A61K 47/6801, A61P 43/00, A61K 31/708, A61K 39/395, A61K 45/00, A61K2039/505, C07K 16/00, C07K 16/28, C07K 16/2863, C07K 16/2896, C07K2317/41, C07K2317/52, C07K2317/524, C07K2317/565, C07K2317/71Filed as DAIICHI SANKYO COMPANY, LIMITED2025-02-26Kyoko HARA | pending |
| METHOD FOR PRODUCING Fc-CONTAINING MOLECULEC07K 16/28, C12P 21/005, C12P 21/02, C07K 1/18, C07K 16/2863, C07K 16/2875, C07K 16/30, C07K 16/32, C07K2317/41, C07K2317/52, C07K2319/00, C12N 9/24, C12N 9/2402, C12Y 302/01096Filed as DAIICHI SANKYO COMPANY, LIMITED2025-02-19Hiroshi MUTO | pending |
| ANTI-MUC1 ANTIBODYA61K 47/6851, C07K 16/3092, A61K 47/65, A61K 47/545, A61K 47/6803, A61P 35/02, A61P 35/04, A61P 35/00, A61K 47/68037, G01N 33/575, A61K 31/4745, A61K 39/39558, A61K 45/00, A61K 45/06, A61K 47/22, A61K2039/505, B66B 5/22, C07K 16/30, C07K2317/14, C07K2317/24, C07K2317/41, C07K2317/55, C07K2317/565, C07K2317/73, C07K2317/76, C07K2317/92Filed as DAIICHI SANKYO COMPANY, LIMITED2025-02-13Johanna GELLERT | pending |
| NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESEC07H 1/00, C07H 19/04, C08B 37/00, Y02P 20/55, C07H 15/203, C08B 37/0003Filed as DAIICHI SANKYO COMPANY, LIMITED2025-02-11Tsuyoshi UEDA | pending |
| ANTI-CD25 ANTIBODY AND ANTI-CD25 ANTIBODY-DRUG CONJUGATEC07K 16/2866, A61K 47/6889, A61K 47/6849, A61P 35/00, A61K 47/68037, A61K 39/3955, C07K2317/24Filed as Daiichi Sankyo Company, Limited2025-02-07Kota Sawano | pending |
| COMBINATION OF ANTIBODY-DRUG CONJUGATE AND BISPECIFIC CHECKPOINT INHIBITORA61K 47/68037, A61K 47/6851, A61K 47/6855, A61P 35/00, A61K 39/3955, A61K2039/507, A61K2300/00, C07K 16/2803, C07K 16/2818, C07K 16/2827, C07K 16/30, C07K 16/32, C07K2317/31, C07K2317/71, C07K2317/76Filed as DAIICHI SANKYO COMPANY, LIMITED2025-01-22Jerome Thomas METTETAL II | pending |
| COMBINATIONS FOR THE TREATMENT OF CANCERFiled as DAIICHI SANKYO COMPANY, LIMITED2025-01-21Jaime Alberto MEJIA | pending |
| POLYNUCLEOTIDES ENCODING ANTIBODIES WHICH BIND THE EC3 DOMAIN OF CADHERIN-6 (CDH6) AND POSSESS INTERNALIZATION ABILITYA61K 9/0019, A61K 39/395, C07K 16/28, A61K 47/68, A61K 47/6851, A61K 47/6861, A61K 47/6869, A61K 47/6849, A61P 13/12, A61P 15/08, A61P 35/00, A61K 47/68037, A61K 47/68033, A61K 9/0021, A61K 9/08, A61K 9/19, A61K 31/4745, A61K 47/10, A61K 47/26, A61K2039/505, C07K2317/24, C07K2317/33, C07K2317/40, C07K2317/41, C07K2317/565, C07K2317/73, C07K2317/732, C07K2317/76, C07K2317/77, C07K2317/92, C12N 5/16, C12N 5/163, C12N2510/02Filed as DAIICHI SANKYO COMPANY, LIMITED2025-01-21Atsuko Saito | pending |
| COMBINATIONS FOR THE TREATMENT OF CANCERFiled as DAIICHI SANKYO COMPANY, LIMITED2025-01-06Eliav BARR | pending |
| TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF ANTIBODY-DRUG CONJUGATEA61K 47/6851, A61P 35/00, A61K 47/68037, A61K 39/395, A61K 47/6843, A61K 47/6889, A61K 47/68, A61K 47/545, A61K 47/6803, A61K 47/6849, A61K 47/6855, A61P 35/02, A61P 35/04, A61K2039/80, A61K 31/4745, A61K2039/505, C07K 16/18, C07K 16/28, C07K 16/2827, C07K 16/30, C07K 16/32, C07K2317/24Filed as DAIICHI SANKYO COMPANY, LIMITED2024-12-24Kiyoshi SUGIHARA | pending |
| ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINESA61K 47/6803, A61P 35/00, A61K 47/68035, C07K 16/28, C07K 16/30, A61K 47/6889, A61K 47/65, A61K 47/6851, A61K 47/6849, A61K 47/6855, A61K 47/6801, A61K 47/68033, A61K 47/68031, A61K 31/5513, A61K 35/00, A61K 39/395, A61K 51/1093, A61K2039/505, C07D 487/04, C07D 519/00, C07K 16/00, C07K 16/1203, C07K 16/18, C07K 16/2878, C07K 16/2896, C07K 16/32, C07K2317/24, C07K2317/41, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/71, C07K2317/77, C07K2317/92, C12P 1/00, C12P 21/00, C12P 21/005Filed as Daiichi Sankyo Company, Limted2024-12-12Narihiro TODA | pending |
| COMBINATIONS FOR THE TREATMENT OF CANCERFiled as DAIICHI SANKYO COMPANY, LIMITED2024-12-09Maria Catherine PIETANZA | pending |
| COMBINATIONS FOR THE TREATMENT OF CANCERFiled as DAIICHI SANKYO COMPANY, LIMITED2024-12-04Bin ZHAO | pending |
| DOSAGE REGIMEN OF AN ANTI-CDH6 ANTIBODY-DRUG CONJUGATEA61K 47/6849, A61K 47/68037, A61K 47/6889, A61K 47/6803, A61P 35/00, C07K 5/1008Filed as DAIICHI SANKYO COMPANY, LIMITED2024-11-22Robert Mcleod | pending |
| COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-SIRPa ANTIBODYA61K 47/6801, C07K 16/2803, A61K 47/6851, A61K 47/6849, A61K 47/6855, A61P 43/00, A61P 35/02, A61P 35/00, A61K 47/68037, A61K 47/68033, A61K 47/68031, A61K 31/40, A61K 31/421, A61K 31/4745, A61K 31/537, A61K 38/00, A61K 38/07, A61K 39/395, A61K2039/505, A61K2039/507, A61K2039/545, A61K2300/00, C07K 16/30, C07K 16/32, C07K2317/56, C07K2317/73, C07K2317/92Filed as DAIICHI SANKYO COMPANY, LIMITED2024-11-04Norihito KAWASAKI | pending |
| PROMOTER OF Eno1 GENEC07K 16/00, C12N 15/63, C12P 21/02, A01K2217/05, A01K2227/105, C07K2317/14, C07K2317/24, C12N 9/88, C12N 15/85, C12N2830/50, C12P 21/00, C12Y 402/01011Filed as DAIICHI SANKYO COMPANY, LIMITED2024-10-25Maui NISHIO | pending |
| PEPTIDE LIBRARY AND USE THEREOFC07K 7/08, C07K 1/047, C07K 14/81, C07K 14/811, C12N 15/1037, C12N 15/1044, C12N2510/00, C12Q 1/37, C40B 50/00, G01N2500/00, G01N2500/04Filed as Daiichi Sankyo Company, Limited2024-10-15Daisuke Nishimiya | pending |
| POLYNUCLEOTIDE ENCODING MEMBRANE-TYPE CYTOKINE AND INTRACELLULAR DOMAIN OF TNF RECEPTOR SUPERFAMILY MOLECULEA61K 35/17, C07K 14/5443, A61P 37/04, A61P 35/00, A61K2239/28, A61K2239/48, A61K2239/22, A61K2239/31, A61K2239/38, A61K 40/35, A61K 40/4215, A61K 40/4255, A61K 40/4202, A61K 40/15, A61K 40/4211, A61K 40/31, A61K 40/421, A61K 40/11, C07K 14/435, C07K 14/54, C07K 14/5418, C07K 14/55, C07K 14/7051, C07K 14/70517, C07K 14/70521, C07K 14/70578, C07K 14/715, C07K 14/7155, C07K 19/00, C07K2319/00, C07K2319/03, C12N 5/06, C12N 5/0636, C12N 5/0646, C12N 5/10, C12N 15/11, C12N 15/62, C12N 15/63, C12N 15/85, C12N2510/00, C12N2830/34Filed as Daiichi Sankyo Company, Limited2024-10-08Kazunori YOSHIKIYO | pending |
| ANTI-CD37 ANTIBODY-DRUG CONJUGATEA61K 47/6851, A61K 47/6849, A61P 35/00, A61K 31/4745, A61K 47/6889, A61K 47/68, A61K 47/6803, A61P 35/02, A61K 47/68037, A61K 39/395, A61K 45/00, C07K 16/00, C07K 16/28, C07K 16/2896, C07K 16/46, C07K 19/00, C12N 15/62Filed as DAIICHI SANKYO COMPANY, LIMITED2024-10-07Tomoko TERAUCHI | pending |
| COMPOSITION FOR CYTOTOXIC T CELL DEPLETIONC07K 16/2803, A61P 37/06, A61K 39/0008, A61K2039/505, A61K2039/577, C07K 16/46, C07K2317/51, C07K2317/515Filed as Daiichi Sankyo Company, Limited2024-09-26Ryuta Mukasa | pending |
| ANTIBODY-DRUG CONJUGATEA61K 47/6889, A61K 31/4745, Y02P 20/55, A61K 47/6803, A61K 47/6849, A61P 43/00, A61P 35/00, A61K 47/68037, A61K 31/48, C07D 491/22, C07K 16/2803, C07K 16/2827, C07K 16/2851, C07K 16/2875, C07K 16/2878, C07K 16/30, C07K2317/30, C07K2317/77Filed as DAIICHI SANKYO COMPANY, LIMITED2024-09-19Takeshi MASUDA | pending |
| A SCORING METHOD FOR AN ANTI-TROP2 ANTIBODY-DRUG CONJUGATE THERAPYG01N 33/5759, A61K 47/6851, A61K 47/6801, G01N2474/20, A61K 47/68037, C07K 16/30, G01N 1/30, G01N2001/302, G01N2333/705, G01N2800/52, G06T 7/0012, G06T2207/10056, G06T2207/30024Filed as DAIICHI SANKYO COMPANY, LIMITED2024-09-12Andreas SPITZMUELLER | pending |
| COMBINATION OF MULTISPECIFIC MOLECULE AND IMMUNE CHECKPOINT INHIBITORA61K 39/395, A61K 39/39558, A61K 45/06, A61K 47/643, A61P 35/02, A61P 35/00, A61K 31/337, A61K 31/47, A61K 31/704, A61K 31/706, A61K 39/3955, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545, A61K2300/00, C07K 16/28, C07K 16/2809, C07K 16/2818, C07K 16/2827, C07K 16/2833, C07K 16/30, C07K 16/44, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/73Filed as DAIICHI SANKYO COMPANY, LIMITED2024-09-12Junya ICHIKAWA | pending |
| siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2A61P 7/02, C12N 15/1138, A61K 47/549, A61P 7/06, A61P 43/00, A61K 31/7088, A61K 31/712, A61K 31/7125, A61K 31/713, C07H 21/02, C07H 21/04, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/351, C12N2310/3521, C12N2310/3533Filed as Daiichi Sankyo Company, Limited2024-09-12Makoto KOIZUMI | pending |
| CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITYA61P 43/00, C12N 15/113, C12N 15/1138, A61K 47/549, A61K 31/712, A61K 31/7125, A61K 31/713, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/351, C12N2310/3533, C12N2310/3521, C12N2310/3525Filed as Daiichi Sankyo Company, Limited2024-09-12Makoto KOIZUMI | pending |
| GRISEOFULVIN COMPOUNDA61K 31/343, C07D 307/94, C07D 413/04, A61P 1/02, A61P 19/00, A61P 43/00, A61P 1/16, A61P 37/06, A61P 19/02, A61P 37/08, A61P 29/00, A61P 17/04, A61K 31/4155, A61K 31/4245, C07D 405/04, C07D 405/10, C07D 407/12, C07D 413/10, C07D 413/14Filed as Daiichi Sankyo Company, Limited2024-08-29Keiji Saito | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on DSNKY
Company overviewEverything on DSNKY in one place, with the price.Who owns itEvery manager reporting a position in DSNKY.LobbyingWhat DSNKY spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on DSNKY's account, and who they worked for.Federal contractsWhat federal agencies pay DSNKY.